KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $163.6 million.

  • Aquestive Therapeutics' Liabilities and Shareholders Equity rose 48.75% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.9 million, marking a year-over-year increase of 11.20%. This contributed to the annual value of $101.4 million for FY2024, which is 76.64% up from last year.
  • Aquestive Therapeutics' Liabilities and Shareholders Equity amounted to $163.6 million in Q3 2025, which was up 74.56% from $93.7 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $163.6 million for Q3 2025, and its period low was $51.8 million during Q3 2022.
  • In the last 3 years, Aquestive Therapeutics' Liabilities and Shareholders Equity had a median value of $101.4 million in 2024 and averaged $95.7 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 111.35% in 2024, then decreased by 21.07% in 2025.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Liabilities and Shareholders Equity stood at $62.0 million in 2021, then dropped by 7.94% to $57.1 million in 2022, then rose by 0.61% to $57.4 million in 2023, then surged by 76.64% to $101.4 million in 2024, then soared by 48.75% to $163.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $163.6 million in Q3 2025, compared to $93.7 million in Q2 2025 and $102.2 million in Q1 2025.